Human Faecal Microbiota in Type 2 Diabetes
26 февраля 2016 г. обновлено: Société des Produits Nestlé (SPN)
Analysis of the Diversity of Faecal Bacteria in Healthy and Type 2 Diabetic Subjects
The main objective of the clinical trial is to investigate whether overweight type 2 diabetic patients have a different fecal microbiota profile compared with age, gender, BMI matched subjects and with lean healthy subjects before and after the consumption of fiber rich cereal bars.
Обзор исследования
Статус
Завершенный
Условия
Вмешательство/лечение
Подробное описание
Gut microbiota refers to the bacterial communities in the gastrointestinal tract.
The diversity and quantity of bacteria vary depending on age of the individuals, daily diet and the segment of the intestine, which makes the gut microbiota one of the most complex bacterial ecosystems known to men.
In general, over trillions of bacteria reside in human gut.
Recent evidence indicates that gut microbiota could be involved in host metabolism by multiple pathways leading to the development of obesity and type 2 diabetes.
Increased fat storage or obesity has become one of the leading public health issues in many developed and developing countries.
However, it is not clear whether type 2 diabetes is associated with a unique gut microbiota profile.
Therefore, the primary objective of the study is to compare the fecal microbiota of overweight type 2 diabetic subjects to that of age, gender and BMI matched subjects as well as with lean non-diabetic subjects.
In addition, the investigators hypothesize that microbiota modifications with consumption of fiber rich food products can improve the metabolic outcomes of type 2 diabetics.
To test this hypothesis, the investigators plan to provide each overweight participant with two cereal bars per day for 4 weeks.
Anthropometric measurements and plasma parameters as well as the fecal microbiota will be determined.
Тип исследования
Интервенционный
Регистрация (Действительный)
67
Фаза
- Непригодный
Критерии участия
Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.
Критерии приемлемости
Возраст, подходящий для обучения
От 30 лет до 55 лет (Взрослый)
Принимает здоровых добровольцев
Да
Полы, имеющие право на обучение
Все
Описание
Inclusion Criteria:
-All diabetic and control non-diabetic subjects (of same BMI) must comply with all the following inclusion criteria:
- Ethnic background: Caucasian
- BMI: 25 to 40 kg/m2
- Fasting blood glucose > 7 mmol/L
- Fasting Hemoglobin A1c > 7%
- Consume mainly typical Western diets daily
- Having obtained his/her informed consent
Lean non-diabetic healthy subjects must comply with the following inclusion criteria:
- Ethnic background: Caucasian
- BMI: 20 to 25 kg/m2
- Fasting blood glucose < 5.5 mmol/L
- Fasting Hemoglobin A1c < 6 %
- Consume mainly typical Western diets daily
- Having obtained his/her informed consent
Exclusion Criteria:
Diabetic and healthy (same BMI) subjects representing one or more of the following criteria are excluded from participation in the study.
- Dietary supplements or medications known to alter gut bacteria, such as antibiotic medication or intestinal transit modulators
- People actively take cortisol or dexamethasone should be excluded from the study
- People under a-amylase/a-glucosidase inhibitors should be excluded from the study. However, patients under metformin can be accepted for this study.
- Patients under metformin suffering from gastrointestinal side effects within a 6-month time period prior to the trial
- Regular consumption of fermented dairy products
- Vegetarians
- Frequent diarrhea (more than two loose stool per day) within 7 days before the enrollment
- HIV seropositive
- Having known gastrointestinal diseases such as ulcerative colitis, Crohn's disease, peptic ulcers and cancer
- Patients who cannot be expected to comply with treatment
- Currently participating or having participated in another clinical trial during the last 6 months prior to the beginning of this study
- Females with hormone therapy will be excluded from the study
Lean healthy subjects representing one or more of the following criteria are excluded from participation in the study.
- Dietary supplements or medications known to alter gut bacteria, such as antibiotic medication or intestinal transit modulators
- Regular consumption of fermented dairy products
- Vegetarians
- Frequent diarrhea (more than two loose stool per day) within 7 days before the enrollment
- HIV seropositive
- Having known gastrointestinal diseases such as ulcerative colitis, Crohn's disease, peptic ulcers and cancer
- Patients who cannot be expected to comply with treatment
- Currently participating or having participated in another clinical trial during the last 6 months prior to the beginning of this study
- Females with hormone therapy will be excluded from the study
Учебный план
В этом разделе представлена подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.
Как устроено исследование?
Детали дизайна
- Основная цель: Фундаментальная наука
- Распределение: Нерандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Без вмешательства: Lean non diabetic
Lean and healthy subjects receiving no intervention
|
|
|
Экспериментальный: Overweight non diabetic
fiber rich cereal bars, two bars a day for 4 weeks
|
Two cereals per day and per subject for 4 weeks
Другие имена:
|
|
Экспериментальный: Overweight diabetic
fiber rich cereal bars, two bars a day for 4 weeks
|
Two cereals per day and per subject for 4 weeks
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Fecal microbiota profile
Временное ограничение: Baseline samples taken after 2 weeks of diet normalization period
|
Fecal samples taken after the two week diet normalization are subjected to bacteria 16S rDNA sequencing and by quantitative PCR.
|
Baseline samples taken after 2 weeks of diet normalization period
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Metabonomic analysis in faeces
Временное ограничение: Samples taken after 2 weeks of diet normalization period (baseline) and 4 weeks of cereal bars intake when applicable
|
Samples for lean non-diabetic, overweight non-diabetic and overweight diabetic subjects.
Post intervention samples from overweight non-diabetic and diabetic subjects.
Then, samples are analyzed by 1HNMR.
|
Samples taken after 2 weeks of diet normalization period (baseline) and 4 weeks of cereal bars intake when applicable
|
|
Metabonomic analysis in plasma
Временное ограничение: Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
Baseline samples for lean non-diabetic, overweight non-diabetic and overweight diabetic subjects.
Post intervention samples from overweight non-diabetic and diabetic subjects.
Then, samples are analyzed by 1HNMR.
|
Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
|
Metabonomic analysis in urine
Временное ограничение: Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
Baseline samples for lean non-diabetic, overweight non-diabetic and overweight diabetic subjects.
Post intervention samples from overweight non-diabetic and diabetic subjects.
Then, samples are analyzed by 1HNMR.
|
Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
|
Plasma glucose
Временное ограничение: Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
Baseline samples for lean non-diabetic, overweight non-diabetic and overweight diabetic subjects.
Post intervention samples from overweight non-diabetic and diabetic subjects.
|
Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
|
Plasma insulin
Временное ограничение: Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
Baseline samples for lean non-diabetic, overweight non-diabetic and overweight diabetic subjects.
Post intervention samples from overweight non-diabetic and diabetic subjects.
|
Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
|
Plasma free fatty acids
Временное ограничение: Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
Baseline samples for lean non-diabetic, overweight non-diabetic and overweight diabetic subjects.
Post intervention samples from overweight non-diabetic and diabetic subjects.
|
Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
|
Plasma triglycerides
Временное ограничение: Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
Baseline samples for lean non-diabetic, overweight non-diabetic and overweight diabetic subjects.
Post intervention samples from overweight non-diabetic and diabetic subjects.
|
Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
|
Plasma total cholesterol
Временное ограничение: Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
Baseline samples for lean non-diabetic, overweight non-diabetic and overweight diabetic subjects.
Post intervention samples from overweight non-diabetic and diabetic subjects.
|
Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
|
Plasma HDL cholesterol
Временное ограничение: Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
Baseline samples for lean non-diabetic, overweight non-diabetic and overweight diabetic subjects.
Post intervention samples from overweight non-diabetic and diabetic subjects.
|
Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
Соавторы и исследователи
Здесь вы найдете людей и организации, участвующие в этом исследовании.
Соавторы
Следователи
- Главный следователь: Alain Golay, Prof, University Hospital, Geneva
Даты записи исследования
Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.
Изучение основных дат
Начало исследования
1 сентября 2007 г.
Первичное завершение (Действительный)
1 июня 2009 г.
Завершение исследования (Действительный)
1 апреля 2011 г.
Даты регистрации исследования
Первый отправленный
18 февраля 2016 г.
Впервые представлено, что соответствует критериям контроля качества
26 февраля 2016 г.
Первый опубликованный (Оценивать)
29 февраля 2016 г.
Обновления учебных записей
Последнее опубликованное обновление (Оценивать)
29 февраля 2016 г.
Последнее отправленное обновление, отвечающее критериям контроля качества
26 февраля 2016 г.
Последняя проверка
1 февраля 2016 г.
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 06.42.NRC
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
НЕТ
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .